靶向PSMA放射性小分子药物研究进展

Research Progress of PSMA-Targeted Small Molecule Drugs

  • 摘要: 前列腺癌(PCa)是男性死亡的常见诱因,严重危害着人们的生命健康。随着靶向前列腺特异性膜抗原(PSMA)的放射性药物在PET/CT和SPECT/CT中的应用,前列腺癌诊断的灵敏度与精确度得到了有效提高。本文首先对靶向PSMA小分子药物的核心结构单元进行介绍,然后重点介绍基于脲基发展而来的靶向PSMA放射性药物(放射性核素包括:68Ga、18F、11C、99mTc、64Cu、123I、125I、131I、177Lu、225Ac、213Bi和212Pb等),以及在前列腺癌中的诊断与治疗研究进展,最后对该研究领域进行总结与展望。

     

    Abstract: Prostate cancer (PCa) is one of the most common reasons for male death, seriously endangering human life and health. With the application of prostate specific membrane antigen PSMAtargeted radiopharmaceuticals in PET/CT and SPECT/CT, the sensitivity and accuracy of diagnosis have been efficiently improved. In this paper, we firstly introduce the core structures of PSMAtargeted small molecule drugs. Then ureabased PSMAtargeted radiopharmaceuticals (radionuclides include 68Ga, 18F, 11C, 99mTc, 64Cu, 123I, 125I, 131I, 177Lu, 225Ac, 213Bi, 212Pb, etc.) and recent progress in diagnosis and therapy are highlighted. Finally, this research field is summarized and prospected.

     

/

返回文章
返回